EP1179083A4 - Triple hybrid amplicon vector systems to generate retroviral packaging lines - Google Patents

Triple hybrid amplicon vector systems to generate retroviral packaging lines

Info

Publication number
EP1179083A4
EP1179083A4 EP00923545A EP00923545A EP1179083A4 EP 1179083 A4 EP1179083 A4 EP 1179083A4 EP 00923545 A EP00923545 A EP 00923545A EP 00923545 A EP00923545 A EP 00923545A EP 1179083 A4 EP1179083 A4 EP 1179083A4
Authority
EP
European Patent Office
Prior art keywords
retrovirus
vector
cells
hsv
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00923545A
Other languages
German (de)
French (fr)
Other versions
EP1179083A1 (en
Inventor
Miguel Sena-Esteves
Xandra O Breakefield
Yoshinaga Saeki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1179083A1 publication Critical patent/EP1179083A1/en
Publication of EP1179083A4 publication Critical patent/EP1179083A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a triple hybrid vector amplicon system comprising genetic elements derived from Herpes Simplex Virus (HSV), Epstein-Barr Virus (EBV) or Adeno-Associated Virus (AAV), and a retrovirus. The vector was developed to stably transform cells, both in culture or in vivo, into retrovirus packaging cells in a single step. This step can be accomplished both by transfection using liposomes, electroporation, calcium phosphate, or any other methodology used to transfer naked or complexed DNA into cells or by infection when the vector is packaged as an amplicon vector in HSV virions. In one embodiment, the system takes advantage of the host range and retention properties of HSV/EBV hybrid amplicons to efficiently convert cells to retrovirus vector producer cells after single-step transduction. Retrovirus genes gag-pol and env (GPE) and retroviral vector sequences were modified to minimize sequence overlap and cloned into an HSV/EBV hybrid amplicon. In a second embodiment, retrovirus gag-pol and env genes and a retrovirus vector carrying lacZ, were cloned into HSV/AAV hybrid amplicons. These hybrid amplicon vector systems hold great potential for the generation of new retrovirus packaging lines derived from cells that due to their migratory, tumor or tissue targeting properties, can expand the spatial distribution of gene delivery by retrovirus vectors in vivo.
EP00923545A 1999-04-22 2000-04-21 Triple hybrid amplicon vector systems to generate retroviral packaging lines Withdrawn EP1179083A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13055199P 1999-04-22 1999-04-22
US130551P 1999-04-22
PCT/US2000/010669 WO2000065077A1 (en) 1999-04-22 2000-04-21 Triple hybrid amplicon vector systems to generate retroviral packaging lines

Publications (2)

Publication Number Publication Date
EP1179083A1 EP1179083A1 (en) 2002-02-13
EP1179083A4 true EP1179083A4 (en) 2003-04-23

Family

ID=22445216

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00923545A Withdrawn EP1179083A4 (en) 1999-04-22 2000-04-21 Triple hybrid amplicon vector systems to generate retroviral packaging lines

Country Status (3)

Country Link
EP (1) EP1179083A4 (en)
AU (1) AU4364700A (en)
WO (1) WO2000065077A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3380605A1 (en) 2015-11-24 2018-10-03 GlaxoSmithKline Intellectual Property Development Limited Transient transfection method for retroviral production
RU2752498C2 (en) * 2015-11-24 2021-07-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Stable cell lines for retroviruses production

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021345A1 (en) * 1996-11-12 1998-05-22 The General Hospital Corporation Hsv/aav hybrid amplicon vectors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830725A (en) * 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US5830727A (en) * 1995-11-18 1998-11-03 Human Gene Therapy Research Institute Herpes simplex virus amplicon mini-vector gene transfer system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021345A1 (en) * 1996-11-12 1998-05-22 The General Hospital Corporation Hsv/aav hybrid amplicon vectors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SAVARD N ET AL: "Defective herpes simplex virus type 1 vectors harboring gag, pol, and env genes can be used to rescue defective retrovirus vectors", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 5, 1 May 1997 (1997-05-01), pages 4111 - 4117, XP002097711, ISSN: 0022-538X *
See also references of WO0065077A1 *
SENA-ESTEVES M ET AL: "SINGLE-STEP CONVERSION OF CELLS TO RETROVIRUS VECTOR PRODUCERS WITH HERPES SIMPLEX VIRUS-EPSTEIN-BARR VIRUS HYBRID AMPLICONS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 12, December 1999 (1999-12-01), pages 10426 - 10439, XP000857997, ISSN: 0022-538X *
WANG S ET AL: "A HYBRID HERPESVIRUS INFECTIOUS VECTOR BASED ON EPSTEIN-BARR VIRUS AND HERPES SIMPLEX VIRUS TYPE 1 FOR GENE TRANSFER INTO HUMAN CELLS IN VITRO AND IN VIVO", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 12, December 1996 (1996-12-01), pages 8422 - 8430, XP000946704, ISSN: 0022-538X *

Also Published As

Publication number Publication date
EP1179083A1 (en) 2002-02-13
WO2000065077A8 (en) 2001-10-11
WO2000065077A1 (en) 2000-11-02
AU4364700A (en) 2000-11-10

Similar Documents

Publication Publication Date Title
Schaal et al. Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion
Wilkie et al. Hybrid plasmids containing an active thymidine kinase gene of Herpes simplex virus 1
Kanda et al. Highly efficient CRISPR/Cas9-mediated cloning and functional characterization of gastric cancer-derived Epstein-Barr virus strains
Accotto et al. Mapping of Digitaria streak virus transcripts reveals different RNA species from the same transcription unit.
NZ500740A (en) Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
AU8067698A (en) Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus
WO1997007225A3 (en) High efficiency retroviral packaging system
WO2000034497A3 (en) Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
US7981676B2 (en) Method for transfer of molecular substances with prokaryotic nucleic acid-binding proteins
Corbeau et al. Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system
Hirai et al. Use of EBV-based vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms
WO2004067710A3 (en) Compositions and methods for tissue specific targeting of lentivirus vectors
WO2003093417A3 (en) Lentiviral vector particles resistant to complement inactivation
PL324289A1 (en) Encapsulated cells producing virus particles
CN101302537B (en) Site-specific integration retroviral vector system and preparation thereof
WO2000065077A8 (en) Triple hybrid amplicon vector systems to generate retroviral packaging lines
EP0816487A4 (en) Recombinant human immunodeficiency virus-producing cell
AU1391295A (en) Ribozymes targeting the retroviral packaging sequence expression construct s and recombinant retroviruses containing such constructs
AU5318496A (en) Adenovirus vectors for gene therapy
Spannaus et al. The prototype foamy virus protease is active independently of the integrase domain
WO2001044458A3 (en) Bovine immunodeficiency virus (biv) based vectors
Zhang et al. Targeted deletion of glycoprotein B gene by CRISPR/Cas9 nuclease inhibits gallid herpesvirus type 3 in dually infected Marek’s disease virus-transformed lymphoblastoid cell line MSB-1
Okada et al. In situ generation of pseudotyped retroviral progeny by adenovirus‐mediated transduction of tumor cells enhances the killing effect of HSV‐tk suicide gene therapy in vitro and in vivo
CA2331440A1 (en) Amphotropic retrovirus packaging cell line, process for its production and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030306

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/867 B

Ipc: 7C 12N 5/10 B

Ipc: 7C 12N 15/38 B

Ipc: 7C 12N 15/63 B

Ipc: 7C 12N 15/869 B

Ipc: 7A 61K 48/00 B

Ipc: 7C 12N 15/864 A

Ipc: 7C 12N 15/64 B

Ipc: 7C 12N 15/86 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030521